To accomplish this, we measured cancer growth, survival, and apoptosis using different apoptotic markers in PPARGC1A-deficient (siPPARGC1A and SR-18292 treatment) FaDu-MOCK or FaDu-CLU cells during cisplatin treatment. The gene discussed is PPARGC1A; the disease is cancer.